Carregant...
A 6-week, double-blind, placebo- and haloperidol-controlled, phase II study of lurasidone in patients with acute schizophrenia
OBJECTIVE: The objective of this study was to evaluate the short-term efficacy and safety of the atypical antipsychotic agent lurasidone in the treatment of schizophrenia. METHODS: In this phase II, randomized, double-blind, placebo-controlled study, hospitalized adult patients diagnosed with schizo...
Guardat en:
| Publicat a: | Ther Adv Psychopharmacol |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SAGE Publications
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4722503/ https://ncbi.nlm.nih.gov/pubmed/26834965 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2045125315606027 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|